Using OCZ103-OS in Patients With Unresectable and Locally Recurrent or Metastatic Colorectal Cancer Undergoing Standard Chemotherapy

A Phase II Clinical Study Using OCZ103-OS in Patients With Unresectable and Locally Recurrent or Metastatic Colorectal Cancer Undergoing Standard Chemotherapy (mFOLFOX6 or FOLFIRI) as Second-Line Treatment

The purpose of this study is to investigate the safety and efficacy of the use of OCZ103-OS in combination with standard of care as a second line treatment in subjects with unresectable and locally recurrent or metastatic colorectal cancer.

Study Overview

• Status: Completed
• Conditions: Colorectal Cancer
• Intervention / Treatment: Drug: OCZ103-OS [pentamidine bis(2-hydroxyethanesulfonate)], mFOLFOX6 or FOLFIRI

Detailed Description

This is a single arm, open label study to investigate the safety and efficacy of the use of OCZ103-OS in combination with standard therapy (mFOLFOX6 or FOLFIRI) as a second line treatment in subjects with unresectable and locally recurrent or metastatic colorectal cancer.

• Study Type: Interventional
• Enrollment (Actual): 53
• Phase: Phase 2

Contacts and Locations

Study Locations

• Canada
  • Quebec, Canada, G1R 2J6
    • Hotel-Dieu de Quebec
  • Quebec
    • Greenfield Park, Quebec, Canada, J4V 2H1
      • CSSS Champlain - Charles-Lemoyne Hospital
    • Levis, Quebec, Canada
      • CSSS Alphonse-Desjardins (CHAU Hotel-Dieu de Levis)
    • Montreal, Quebec, Canada, H3T 1E2
      • Jewish General Hospital
    • Montreal, Quebec, Canada, H2X 3J4
      • CHUM-St. Luc Hospital
    • Sherbrooke, Quebec, Canada, J1H 5N4
      • CHUS-Centre de recherche Etienne-Le Bel
    • St-Jérome, Quebec, Canada
      • CSSS St-Jérome

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. Histologically or cytologically proven diagnosis of adenocarcinoma of the colon/rectum with evidence of (1) unresectable and, locally recurrent, or (2) metastatic disease.
2. Failure of first-line therapy(5-Fu-based therapy +/- bevacizumab) for metastatic colorectal cancer.
3. At least one (1) unidimensionally measurable lesion (on spiral CT scan).
4. 18 years of age or older.
5. ECOG performance status 0, 1 or 2.
6. Serum aspartate transaminase (AST), serum alanine transaminase (ALT), serum alkaline phosphatase (ALP) ≤ 2.5 x upper limit of normal (ULN), or AST,ALT, ALP ≤ 5 x ULN if liver function abnormalities are due to underlying malignancy
7. Total serum bilirubin ≤ 1.5 x ULN
8. Lipase and amylase within normal limits or abnormal limits but deemed not clinically significant.
9. Absolute neutrophil count (ANC) ≥ 1500/µL (1.5 x 10e9/L)
10. Platelets ≥ 100,000/µL (100 x 10e9/L)
11. Hemoglobin ≥ 90 g/L

12. Serum creatinine ≤ 1.5 x ULN or calculated creatinine clearance ≥ 60 ml/min. The Cockcroft-Gault formula to be used is as follows:

    eCcr=(140-age)x Mass(in kilogram)x Constant/Serum Creatinine(in µmol/L)

    Where Constant is 1.23 for men and 1.04 for women.

13. Normal or abnormal ECG. If ECG shows abnormalities, they must be deemed not clinically significant.
14. Signed and dated Informed Consent Form indicating that the subject (or legally acceptable representative) has been informed of all the pertinent aspects of the trial prior to enrollment.
15. Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other trial procedures.
16. Life expectancy, in the opinion of the investigator, > 3 months.

Exclusion criteria

1. Systolic Blood Pressure <100 mmHg (if deemed clinically significant by the treating physician).
2. Uncontrolled diabetes, severe renal impairment or pancreatitis.
3. Concomitant therapy with other investigational agents or participation in another clinical trial within 30 days prior to enrollment.
4. Any of the following conditions: Ongoing cardiac dysrhythmias of NCI CTCAE grade ≥ 2; atrial fibrillation of any grade; QTc interval > 450 msec for males or > 470 msec for females or uncontrolled intercurrent illness, e.g. unstable angina; severe coronary disease, ventricular arrhythmias, bradycardia < 50 bpm; a history of additional risk factors for torsades de pointes (e.g., heart failure, hypokalemia or family history of Long QT Syndrome).
5. Active uncontrolled bacterial infection.
6. Concurrent use of drugs that could prolong QT interval (NB: pentamidine is known to induce torsades de pointes) (see Appendix II: List of drugs that could prolong QT interval / we also suggest that you refer to the following link: http://www.azcert.org/medical-pros/drug-lists/bycategory.cfm).
7. Concurrent use of nephrotoxic drugs (depending on the medical health status of the patient and based on the judgment of the investigator), including but not limited to aminoglycosides, ampho B, foscarnet and cidofovir.
8. Concurrent use of drugs such as Rifampine and Lamivudine, since these that may be associated with pancreatitis.
9. Prior malignancy other than colorectal cancer (except for adequately treated carcinoma in situ of the cervix, non-melanoma skin cancer or localized prostate cancer with undetectable PSA level) unless the prior malignancy was diagnosed and definitively treated at least five (5) years previously with no subsequent evidence of recurrence.
10. Clinically significant non-malignant lung disease.
11. History of allergy or hypersensitivity to pentamidine.
12. Pregnancy or breastfeeding. All female patients with reproductive potential must have a negative pregnancy test (serum or urine) prior to first dose of study medication.
13. Severe acute or chronic medical or psychiatric condition, or laboratory abnormality that would impart, in the judgement of the investigator, excess risk associated with trial participation of study drug administration, or which in the judgement of the investigator, would make the subject inappropriate for entry into this trial.
14. Use of oral anticoagulants (LMWH is acceptable)

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: OCZ103-OS, mFOLFOX6 or FOLFIRI; OCZ103-OS in combination with mFOLFOX6 or FOLFIRI as standard of care	Drug: OCZ103-OS [pentamidine bis(2-hydroxyethanesulfonate)], mFOLFOX6 or FOLFIRI; OCZ103-OS is given in combination with Chemotherapy each cycle

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Tumor size (CT scan)	To assess the antitumor activity of OCZ103-OS in combination with standard of care in subjects with unresectable and locally recurrent or metastatic colorectal cancer in terms of tumor growth during treatment	2 years
Progression free survival (PFS)	To assess the antitumor activity of OCZ103-OS in combination with standard of care in subjects with unresectable and locally recurrent or metastatic colorectal cancer in terms of progression free survival	2 years
Overall survival (OS)	To assess the antitumor activity of OCZ103-OS in combination with standard of care in subjects with unresectable and locally recurrent or metastatic colorectal cancer in terms of overall survival	2 years

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Peak plasma concentration (Cmax) of OCZ103-OS	To assess the peak plasma concentration of OCZ103-OS after administration on day 1 of first cycle.; Amount of OCZ103-OS in serum on day 1 of first cycle.	2 months
Number of participants with Adverse Events (AE) as a Measure of Safety and Tolerability	- To assess the number of adverse events in participants due to IV OCZ103-OS in conjunction with standard chemotherapy (mFOLFOX6- or FOLFIRI-contained regimen) in patients with unresectable and locally recurrent or metastatic colorectal cancer requiring second-line chemotherapy from baseline.	2 years
Objective response (OR)	- To assess the effect of OCZ103-OS on overall objective response (OR) in subjects with unresectable and locally recurrent or metastatic colorectal cancer treated concurrently with mFOLFOX6 or FOLFIRI.	2 years
Duration of response (DR)	- To assess the effect of OCZ103-OS on duration of response (DR) in subjects with unresectable and locally recurrent or metastatic colorectal cancer treated concurrently with mFOLFOX6 or FOLFIRI.	2 years

Collaborators and Investigators

• Sponsor: Oncozyme Pharma Inc.
• Investigators: Principal Investigator: Petr Kavan, MD, Ph.D., Jewish General Hospital; Principal Investigator: Benoit Samson, MD, CSSS Champlain - Charles-Lemoyne Hospital; Principal Investigator: Richard Letourneau, MD, St. Luc Hospital; Principal Investigator: Felix Couture, MD, Hotel-Dieu de Quebec; Principal Investigator: Felix Couture, MD, CSSS Alphonse-Desjardins; Principal Investigator: Annie Beaudoin, M.D., CHUS-Centre de recherche Etienne-Le Bel; Principal Investigator: Jacques Jolivet, MD, CSSS St-Jérome

Study record dates

Study Major Dates

• Study Start: March 1, 2011
• Primary Completion (Actual): March 1, 2014
• Study Completion (Actual): July 1, 2014

Study Registration Dates

• First Submitted: June 15, 2011
• First Submitted That Met QC Criteria: June 21, 2011
• First Posted (Estimate): June 22, 2011

Study Record Updates

• Last Update Posted (Estimate): October 21, 2014
• Last Update Submitted That Met QC Criteria: October 20, 2014
• Last Verified: February 1, 2013

More Information

Terms related to this study

• Keywords: Colorectal Cancer; Standard of Care; OCZ103-OS; Pentamidine bis(2-hydroxyethanesulfonate)
• Additional Relevant MeSH Terms: Digestive System Diseases; Neoplasms; Neoplasms by Site; Gastrointestinal Neoplasms; Digestive System Neoplasms; Gastrointestinal Diseases; Colonic Diseases; Intestinal Diseases; Intestinal Neoplasms; Rectal Diseases; Colorectal Neoplasms; Anti-Infective Agents; Antifungal Agents; Antiprotozoal Agents; Antiparasitic Agents; Trypanocidal Agents; Pentamidine
• Other Study ID Numbers: OP-103-C